# Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients

> **NCT00826371** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 114 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT00826371
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826371, "Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00826371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*